Document is current
Any future updates will be listed below
-
Authors
Eskes, Eline C. B.
Beishuizen, Cathrien R. L.
Corazolla, Eleonore M.
van Middelaar, Tessa
Brands, Marion M. M. G.
Dekker, Hanka
van de Mheen, Erica
Langeveld, Mirjam
Hollak, Carla E. M.
Sjouke, Barbara https://orcid.org/0000-0001-8162-9684
- License Information
-
More Information
Article History
Received: 9 June 2022
Accepted: 4 October 2022
First Online: 21 October 2022
Declarations
:
: The need for ethics approval was waived by the Medical Ethics Committee of the Amsterdam UMC, location AMC (W20_380 # 20.425). Participants provided written informed consent prior to the focus group discussions or interviews.
: The consent to publish the results of the study was included in the informed consent.
: CB, EC, TM, HD, and EM have nothing to disclose. EE is involved as a sub-investigator in a pre-marketing study with Sanofi Genzyme. MB was a sub-investigator in the Lysogene gene therapy study for MPS III (NCT02053064). ML and CH are involved in premarketing studies with Sanofi-Genzyme, Protalix and Idorsia. BS is involved in a premarketing study with Protalix.
